4
Changes in Ownership
NEKTAR THERAPEUTICS Filed Acc 0001209191-21-060513
Options or other derivatives
- Chief R&D Officer acquired 71,550 shares (grant or award)
From the SEC's structured data for this filing
Trades in this filing
Zalevsky Jonathan · Chief R&D Officer
Table II: Derivative
1 line| Date | Transaction | Shares | Owned after | D/I |
|---|---|---|---|---|
| 2021-10-12 | Grant or award : show line 1 in the form Stock Option | +71,550 | 71,550 | D |
Loading xslF345X03/doc4.xml…